Search Results
QuANTUM-First: association between FLT3-ITD-specific MRD clearance and survival in patients with AML
QuANTUM-First: FLT3-ITD-specific MRD clearance is associated with improved OS in newly diagnosed AML
Assessing FLT3-ITD-specific MRD clearance using a PCR-NGS assay in the QuANTUM-First trial
Further analysis of QuANTUM-First: the impact of allo-HCT combined with quizartinib in FLT3-ITD+ AML
Update on QuANTUM-First: quizartinib + SOC chemotherapy & as continuation therapy in FLT3-ITD+ AML
Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
The prognostic value of FLT3-ITD residual disease in AML
Quizartinib advances overall survival in acute myeloid leukaemia patients
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Management & outcome of patients with CBF AML and FLT3-ITD
FLT3 mutation clearance rate in patients with newly diagnosed AML
Prognostic impact of FLT3-ITD in older patients with AML
